The Aspergillosis market report also offers comprehensive insights into the Aspergillosis market size, share, Aspergillosis epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Aspergillosis market size growth forward.
Some of the key highlights from the Aspergillosis Market Insights Report:
As per DelveInsight analysis, the Aspergillosis market is anticipated to witness growth at a considerable CAGR
The Aspergillosis market is expected to grow significantly during the forecast period, driven by the introduction of new therapies like Opelconazole and others.
Several key pharmaceutical companies, including Regeneron, Pulmocide, Astellas Pharma, Cipla, Pulmatrix, F2G, Cellix Bio, SCYNEXIS, TFF, Matinas BioPharma, Amplyx Pharmaceuticals, Cidara Therapeutics, ImmuPharma, Takis, and others, are developing novel products to improve the Aspergillosis treatment outlook.
In 2023, the Aspergillosis market in the 7MM was valued at around USD 2,606 million, with expectations to grow at a compound annual growth rate (CAGR) of approximately 11% by 2034.
In 2023, the US reported approximately 568 thousand cases of aspergillosis, with allergic bronchopulmonary aspergillosis (ABPA) accounting for 92% of these cases and chronic pulmonary aspergillosis (CPA) making up only 2%. Both forms are expected to see an increase in prevalence during the forecast period.
In 2023, the UK had a significant share of diagnosed prevalent aspergillosis cases among the EU4 and the UK, reporting around 179 thousand cases, while Spain had the lowest prevalence with nearly 67 thousand cases. This difference underscores the UK’s leading position in the regional aspergillosis landscape, in contrast to Spain’s much smaller case load.
In March 2024, the US FDA granted orphan drug and pediatric exclusivity to CRESEMBA (isavuconazonium sulfate) for treating invasive Aspergillosis and invasive mucormycosis in pediatric patients.
In April 2024, Pulmocide Ltd. announced positive topline results from the OPERA-S Phase II trial, which evaluated inhaled opelconazole in lung transplant patients. The trial showed that opelconazole was well tolerated, with fewer adverse events and drug-drug interactions than standard care, effectively preventing and eradicating pulmonary Aspergillus and Candida infections.
In January 2024, TFF Pharmaceuticals revealed that it would present Phase II trial data on Voriconazole Inhalation Powder (TFF VORI) for treating invasive pulmonary Aspergillosis at the 11th Advances Against Aspergillosis & Mucormycosis Conference in Milan, Italy, highlighting advancements in the treatment of this severe fungal infection.
Strategise your business goals by understanding market dynamics @ Aspergillosis Market Landscape
Aspergillosis Overview
Aspergillosis is a fungal infection caused mainly by *Aspergillus fumigatus*, typically affecting individuals with weakened immune systems or existing lung diseases like COPD or cystic fibrosis. It manifests in different forms, including allergic fungal sinusitis (an immune response causing chronic sinus inflammation), invasive aspergillosis (a life-threatening infection that can spread beyond the lungs in immunocompromised patients), and chronic pulmonary aspergillosis (a long-term lung infection often arising from prior lung damage).
Diagnosis involves a combination of clinical assessment, imaging, and lab tests. Doctors usually start with a medical history and symptom evaluation (persistent cough, fever, chest pain), followed by high-resolution CT scans to detect lung abnormalities typical of aspergillosis.
Do you know the treatment paradigms for different countries? Download our Aspergillosis Market Sample Report
Aspergillosis Epidemiology Segmentation
DelveInsight’s Aspergillosis market report is prepared on the basis of an epidemiology model. It offers comprehensive insights to the Aspergillosis historical patient pools and forecasted Aspergillosis patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Aspergillosis Market report proffers epidemiological analysis for the study period 2020-32 in the 7MM segmented into:
Aspergillosis Prevalence
Age-Specific Aspergillosis Prevalence
Gender-Specific Aspergillosis Prevalence
Diagnosed and Treatable Cases of Aspergillosis
Visit for more @ Aspergillosis Epidemiological Insights
Aspergillosis Market Outlook
Aspergillosis, a serious fungal infection, is treated based on its type and severity, with common options including azoles (like voriconazole and posaconazole), echinocandins (such as caspofungin), and polyenes (like amphotericin B). Azoles are typically the first choice for treatment, targeting fungal cell membranes, while echinocandins are used for severe or drug-resistant cases. Polyenes are reserved for life-threatening infections. Newer therapies, like isavuconazole, offer improved safety and convenience compared to traditional options.
The Aspergillosis treatment market is poised for growth, driven by the introduction of therapies like PC945 and Olorofim, though their long-term success remains uncertain. In 2023, the U.S. market was valued at around USD 1,125 million, with a projected 10% CAGR. Across the EU4 and the UK, the market was about USD 866 million, with the UK leading and Spain having the smallest share. The market is expected to expand further as new therapies are introduced.
Aspergillosis Marketed Aspergillosis Drugs
CRESEMBA: Astellas Pharma/ Basilea Pharmaceutica International
Aspergillosis Emerging Aspergillosis Drugs
Olorofim (F901318): F2G
Opelconazole (PC945): Pulmocide
Aspergillosis Key Companies
Regeneron, Pulmocide, Astellas Pharma, Cipla, Pulmatrix, F2G, Cellix Bio, SCYNEXIS, TFF, Matinas BioPharma, Amplyx Pharmaceuticals, Cidara Therapeutics, ImmuPharma, Takis, and others
For more information, visit Aspergillosis Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Aspergillosis Market Report:
11 Years Forecast
7MM Coverage
Descriptive overview of Aspergillosis, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Aspergillosis epidemiology in the 7MM
Aspergillosis marketed and emerging therapies
Aspergillosis companies
Aspergillosis market drivers and barriers
Table of Contents:
1 Aspergillosis Market Key Comprehensive Insights
2 Aspergillosis Market Report Introduction
3 Competitive Intelligence Analysis for Aspergillosis
4 Aspergillosis Market Analysis Overview at a Glance
5 Executive Summary of Aspergillosis
6 Aspergillosis Epidemiology and Market Methodology
7 Aspergillosis Epidemiology and Patient Population
8 Aspergillosis Patient Journey
9 Aspergillosis Treatment Algorithm, Aspergillosis Current Treatment, and Medical Practices
10 Key Endpoints in Aspergillosis Clinical Trials
11 Aspergillosis Marketed Therapies
12 Aspergillosis Emerging Therapies
13 Aspergillosis: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Aspergillosis
16 Aspergillosis Market Key Opinion Leaders Reviews
18 Aspergillosis Market Drivers
19 Aspergillosis Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Aspergillosis Epidemiology 2034
DelveInsight’s “Aspergillosis – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Aspergillosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Aspergillosis Pipeline 2024
“Aspergillosis Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Aspergillosis market. A detailed picture of the Aspergillosis pipeline landscape is provided, which includes the disease overview and Aspergillosis treatment guidelines.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
